Pharmaceutical company Bristol-Myers Squibb received FDA approval for Augtyro, a drug developed to treat lung cancer. The approval comes after the drug, was successful in a trial of cancer patients.
The drug, which is expected to hit the U.S. market in December 2023, is intended to treat ROS1-positive non-small cell lung cancer (NSCLC) patients, who experience an alteration in their ROS1 gene which causes abnormal formation of cells.
Augtyro is a tyrosine kinase inhibitor (TKI), a treatment designed to track protein mutations that can affect cell growth. A recent clinical trial testing Augtyro was successful, indicating that the drug reduced tumors in nearly 80% of patients, which contributed to its FDA approval.